Management of restless legs syndrome in chronic liver disease: a challenge for the correct diagnosis and therapy by Moretti, Rita et al.
Published by Baishideng Publishing Group Inc
ISSN 1948-5182 (online)
World Journal of 
Hepatology
World J Hepatol  2018 March 27; 10(3): 352-401
Contents Monthly  Volume 10  Number 3  March 27, 2018
March 27, 2018|Volume 10|Issue 3|WJH|www.wjgnet.com I
REVIEW
352	 Reactivation	of	hepatitis	B	after	liver	transplantation:	Current	knowledge,	molecular	mechanisms	and	
implications	in	management
Chauhan R, Lingala S, Gadiparthi C, Lahiri N, Mohanty SR, Wu J, Michalak TI, Satapathy SK
MINIREVIEWS
371	 Metabolomics:	From	liver	chiromancy	to	personalized	precision	medicine	in	advanced	chronic	liver	disease	
Procopet B, Fischer P, Farcau O, Stefanescu H
ORIGINAL ARTICLE
Observational Study
379	 Management	of	restless	legs	syndrome	in	chronic	liver	disease:	A	challenge	for	the	correct	diagnosis	and	
therapy
Moretti R, Caruso P, Tecchiolli M, Gazzin S, Tiribelli C
CASE REPORT
388	 Clostridium paraputrificum 	septicemia	and	liver	abscess
Kwon YK, Cheema FA, Maneckshana BT, Rochon C, Sheiner PA
396	 Liver	failure	caused	by	prolonged	state	of	malnutrition	following	bariatric	surgery
Lammers WJ, van Tilburg AJP, Apers JA, Wiebolt J
LETTERS TO THE EDITOR
400	 Do	Ayurveda	drugs	induce	liver	injury?
Ruknuddin G
Contents
World Journal of Hepatology
Volume 10  Number 3  March 27, 2018
EDITORS FOR 
THIS ISSUE
Responsible Assistant Editor: Xiang Li             Responsible Science Editor: Li-Jun Cui
Responsible Electronic Editor: Xiu-Xia Song             Proofing Editorial Office Director: Ze-Mao Gong
Proofing Editor-in-Chief: Lian-Sheng Ma
NAME	OF	JOURNAL	
World Journal of  Hepatology
ISSN
ISSN 1948-5182 (online)
LAUNCH	DATE
October 31, 2009
FREQUENCY	
Monthly 
EDITOR-IN-CHIEF
Wan-Long Chuang, MD, PhD, Doctor, Professor, 
Hepatobiliary Division, Department of  Internal 
Medicine, Kaohsiung Medical University Hospital, 
Kaohsiung Medical University, Kaohsiung 807, Taiwan
EDITORIAL	BOARD	MEMBERS
All editorial board members resources online at http://
www.wjgnet.com/1948-5182/editorialboard.htm
EDITORIAL	OFFICE
Xiu-Xia Song, Director
World Journal of  Hepatology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, 
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501, 
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com
PUBLICATION	DATE
March 27, 2018
COPYRIGHT
© 2018 Baishideng Publishing Group Inc. Articles pub-
lished by this Open Access journal are distributed under 
the terms of  the Creative Commons Attribution Non-
commercial License, which permits use, distribution, 
and reproduction in any medium, provided the original 
work is properly cited, the use is non commercial and is 
otherwise in compliance with the license.
SPECIAL	STATEMENT
All articles published in journals owned by the 
Baishideng Publishing Group (BPG) represent the 
views and opinions of  their authors, and not the views, 
opinions or policies of  the BPG, except where other-
wise explicitly indicated.
INSTRUCTIONS	TO	AUTHORS
http://www.wjgnet.com/bpg/gerinfo/204
ONLINE	SUBMISSION	
http://www.f6publishing.com
March 27, 2018|Volume 10|Issue 3|WJH|www.wjgnet.com II
ABOUT COVER
AIM AND SCOPE
INDEXING/ABSTRACTING 
Editorial	 Board	Member	of	World	 Journal	 of	Hepatology,	 Jong	Won	Yun,	 PhD,	
Professor,	Department	 of	Biotechnology,	Daegu	University,	 Kyungsan	712-714,	
South	Korea
World Journal of  Hepatology (World J Hepatol, WJH, online ISSN 1948-5182, DOI: 
10.4254), is a peer-reviewed open access academic journal that aims to guide clinical 
practice and improve diagnostic and therapeutic skills of  clinicians.
WJH covers topics concerning liver biology/pathology, cirrhosis and its complications, 
liver fibrosis, liver failure, portal hypertension, hepatitis B and C and inflammatory 
disorders, steatohepatitis and metabolic liver disease, hepatocellular carcinoma, biliary 
tract disease, autoimmune disease, cholestatic and biliary disease, transplantation, genetics, 
epidemiology, microbiology, molecular and cell biology, nutrition, geriatric and pediatric 
hepatology, diagnosis and screening, endoscopy, imaging, and advanced technology. 
Priority publication will be given to articles concerning diagnosis and treatment of  
hepatology diseases. The following aspects are covered: Clinical diagnosis, laboratory 
diagnosis, differential diagnosis, imaging tests, pathological diagnosis, molecular biological 
diagnosis, immunological diagnosis, genetic diagnosis, functional diagnostics, and physical 
diagnosis; and comprehensive therapy, drug therapy, surgical therapy, interventional 
treatment, minimally invasive therapy, and robot-assisted therapy. 
We encourage authors to submit their manuscripts to WJH. We will give priority 
to manuscripts that are supported by major national and international foundations and 
those that are of  great basic and clinical significance.
World Journal of  Hepatology is now indexed in Emerging Sources Citation Index (Web of  
Science), PubMed, PubMed Central, and Scopus.
379 March 27, 2018|Volume 10|Issue 3|WJH|www.wjgnet.com
Rita Moretti, Paola Caruso, Marzia Tecchiolli, Neurology 
Clinic, Department of Medical, Surgical and Health Sciences, 
University of Trieste, Trieste 34149, Italy
Silvia Gazzin, Claudio Tiribelli, Italian Liver Foundation, Centro 
Studi Fegato, Trieste 34149, Italy
ORCID number: Rita Moretti (0000-0002-9731-2697); 
Paola Caruso (0000-0002-1466-6060); Marzia Tecchiolli 
(0000-0003-2474-1500); Silvia Gazzin (0000-0001-9403-3564); 
Claudio Tiribelli (0000-0001-6596-7595).
Author contributions: Moretti R, Caruso P and Gazzin S 
contributed to study conception and design; Moretti R, Caruso P, 
Tecchiolli M and Gazzin S contributed to data acquisition, data 
analysis and interpretation, and writing of the article; Moretti 
R, Caruso P, Tecchiolli M and Tiribelli C contributed to editing, 
reviewing and final approval of the article. 
Institutional review board statement: This observational 
study has been reviewed by the Committee of Research of 
Cattinara Hospital.
Informed consent statement: Participants gave informed 
consent for data sharing.
Conflict-of-interest statement: No conflicting interests 
(commercial, personal, political, intellectual or religious interests) 
are related to this work. The authors do not have any conflict of 
interest to declare. 
Data sharing statement: Technical appendix, statistical code, 
and dataset available from the corresponding author at moretti@
units.it. 
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Invited manuscript
Correspondence to: Rita Moretti, MD, PhD, Senior Scientist, 
Department of Medical, Surgical and Health Sciences, University 
of Trieste, Strada di Fiume 447, Trieste 34149, 
Italy. moretti@units.it
Telephone: +39-40-3994572
Fax: +39-40-3994284 
Received: October 30, 2017
Peer-review started: October 31, 2017
First decision: December 26, 2017
Revised: December 27, 2017
Accepted: January 23, 2018
Article in press: January 23, 2018
Published online: March 27, 2018
Abstract 
AIM
To investigate the association between restless legs 
syndrome (RLS) and well-defined chronic liver disease, 
and the possible therapeutic options. 
METHODS
Two hundred and eleven patients with chronic liver 
disease, complaining of sleep disturbances, painful leg 
sensation and daily sleepiness, were included. Patients 
with persistent alcohol intake, recent worsening of 
clinical conditions, or hepatitis C virus were excluded. 
Diagnosis of RLS was suggested by the Johns Hopkins 
questionnaire and verified by fulfilling the diagnostic 
criteria by Allen. All patients were tested, both at 
baseline and during follow-up, with the Hamilton 
rating scale for depression, sleep quality assessment 
(PSQI), Epworth sleepiness scale (ESS), International 
Restless Legs Syndrome Study Group evaluation, and 
international RLS severity (IRLS) scoring system. Iron-
free level, ferritin, folate, vitamin B12 and D-OH25 were 
detected. Neurological examinations and blood test 
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occurred at the beginning of the therapy, after 2 wk, 
and at the 28th, 75th, 105th, 135th, 165th and 205th day. 
Regarding therapy, pramipexole or gabapentin were 
used.
RESULTS
Patients were moderately depressed, with evident 
nocturnal sleep problems and concomitant daily 
sleepiness. Sleep problems and involuntary leg 
movements had been underestimated, and RLS 
syndrome had not been considered before the 
neurological visit. All (211/211) patients fulfilled the 
RLS diagnostic criteria. Twenty-two patients considered 
their symptoms as mild, according to IRSL, but 189 
found them moderate to very severe. No correlation 
was found between ammonium level and ESS or PSQI. 
Augmentation was rather precocious in our patients 
(135th day), and more frequent (35%) than previous 
data (8.3%-9.1%). The dosage of dopamine agonists 
was found to be associated with augmentation and 
appears in range with the literature. Previous intake of 
alcohol and lower levels of vitamins have been related 
to the phenomenon in our study.
CONCLUSION
RLS is a common disorder, requiring rapid diagnosis and 
treatment. Further research is therefore fundamental. 
Key words: Restless legs syndrome; Chronic liver 
disease; Dopamine agonist treatment; Augmentation
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The diagnosis of restless legs syndrome (RLS) 
relies on the presence of unpleasant sensation in the 
legs associated with the urge to move. Symptoms 
mostly begin during periods of rest or inactivity and 
worsen in the evening or night. Partial or total relief 
is related to movement. Chronic hepatic failure was 
recently described in association with RLS, but there 
are very limited studies, with no mention to treatment. 
We describe RLS syndrome associated with well-
defined chronic liver disease along with therapeutic 
options, discussing risks, benefits and potential side 
effects, with a particular look at the augmentation 
phenomenon in hepatic failure.
Moretti R, Caruso P, Tecchiolli M, Gazzin S, Tiribelli C. 
Management of restless legs syndrome in chronic liver disease: 
A challenge for the correct diagnosis and therapy. World J 
Hepatol 2018; 10(3): 379-387  Available from: URL: http://www.
wjgnet.com/1948-5182/full/v10/i3/379.htm  DOI: http://dx.doi.
org/10.4254/wjh.v10.i3.379
INTRODUCTION
Restless legs syndrome (RLS) is defined as a very 
sickening, bilateral (even if also unilateral) sensation, 
almost described as affecting a very limited zone, 
between the knees and ankles, sometimes involving 
thighs and feet and resulting in feelings of scrambles, 
creeps or crawls. The discomfort is experienced only 
during the rest phase and it is relieved by active 
movement of the legs. Patients describe the symptoms 
of RSL as unbearable, when they are strained to 
maintain the sit-down position, such as during long 
flights or social events. But, usually, sleep is the worst 
moment of the day and RLS can disturb their sleep for 
hours. The American patients’ organization Restless 
Legs Syndrome Foundation reminds us that RLS is 
“the most common disorder you have never heard of” 
(http://www.rls.org). 
RLS remains a clinical diagnosis based on confirming 
the four essential diagnostic features of RLS: (1) 
An urge to move the legs, usually but not always 
accompanied by or felt to be caused by uncomfortable 
and unpleasant sensations in the legs; (2) the urge 
to move, as any accompanying unpleasant sensation 
begins or worsens during periods of rest or inactivity, 
such as lying down or sitting; (3) the urge to move, 
as any accompanying unpleasant sensation is partially 
or totally relieved by movement, such as walking 
or stretching; and (4) the urge to move, as any 
accompanying unpleasant sensation during rest or 
inactivity only occurs or is worse in the evening or night 
compared to during the day[1,2]. Moreover, supportive 
criteria should be found in family history, response to 
dopaminergic therapy and the presence of involuntary, 
rhythmic muscular jerks in the lower limbs, including 
dorsiflexion or fanning of toes, flexion of ankles, knees 
and hips, the so-called periodic limb movements during 
sleep (PLMS)[1,3]. 
Helpful tools to make an accurate RLS diagnosis 
include the Johns Hopkins telephone diagnostic 
interview, medical history (evaluating for four essential 
diagnostic features of RLS and iron deficiency), and 
evaluating and ruling out mimics[4]. RLS frequently 
occurs in patients with kidney disease. 
The prevalence of RLS, which is high in dialysis 
patients and which has been associated with 
increased risk for cardiovascular disease in the general 
population, could also play a role in the pathogenesis 
of hypertension during sleep in renal patients. It should 
be noted that intravenous iron treatment reduces 
the RLS symptoms in patients with end-stage renal 
disease[2]. RLS is common in rheumatologic disorders, 
such as rheumatoid arthritis or Sjögren’s syndrome[1,2], 
but not in isolated peripheral neuropathy, as in 
hereditary neuropathic patients[2]. Some data seem 
to indicate that there is a considerably higher risk for 
developing RLS in migraneous patients, especially in 
those who experienced the dopaminergic anticipatory 
symptoms, such as nausea, somnolence and 
yawning[2]. RLS is also common during pregnancy, 
especially during the last trimester, and iron deficiency 
may be a major cause; the symptoms of RLS 
usually disappear soon after childbirth. An increased 
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prevalence of RLS has been described in patients with 
liver cirrhosis in the United States[5] and Japan[6]. Very 
recently, Goel et al[7] described in India RLS in a series 
of chronic hepatic failure patients.
MATERIALS AND METHODS
This study included 267 adult patients with chronic 
liver disease, referred to our Neurological Unit by the 
Liver Unit of the University of Trieste between June 1, 
2008 and December 1, 2015. The patients had been 
referred to the neurologist for the three complaints 
of sleep disturbances, painful leg sensation, daily 
sleepiness not correlated to hepatic encephalopathy. 
Patients with chronic liver disease included primary 
liver tumor and liver cirrhosis. We excluded 13 patients 
with chronic and persistent significant alcohol intake (> 
30 g/d in men and > 20 g/d in women; to avoid acute 
alcohol polyneuropathy, which might mimic some 
symptoms of RLS and low compliance), 25 patients 
with recent worsening of clinical condition (jaundice, 
ascites or encephalopathy, gastrointestinal bleeding, 
or hospitalization), and 12 patients with hepatitis 
C virus (HCV; to exclude HCV-related peripheral 
complications). 
All the other 211 patients were followed up by a 
neurologist at least for 24 mo (Table 1). According 
to neurological exams, the diagnosis of RLS was 
suggested by the Johns Hopkins questionnaire[4] and 
verified by fulfilling the diagnostic criteria by Allen et 
al[1]. Only 3 patients mentioned a possible familiar 
history of RLS. Iron-free level, ferritin, folate, vitamin 
B12 and vitamin D-OH25 was measured in all patients 
(Table 2).
At baseline, patients were tested with the Hamilton 
rating scale for depression[9], sleep quality assessment 
(PSQI)[10], Epworth sleepiness scale (ESS)[11], 
International Restless Legs Syndrome Study Group 
(IRLSSG) evaluation[12], and international RLS severity 
(IRLS) scoring system[13]. 
The Pittsburgh sleep quality index (PSQI) is an 
effective instrument, employed to measure the quality 
and pattern of sleep in adults. It differentiates “poor” 
from “good” sleep quality by measuring the following 
seven areas (components): Subjective sleep quality; 
sleep latency; sleep duration; habitual sleep efficiency; 
sleep disturbances; use of sleeping medications; and, 
daytime dysfunction over the last month. A total score 
of 5 or greater is indicative of poor sleep quality[10].
The ESS questionnaire asks the subject to rate the 
probability of falling asleep on a scale of increasing 
probability from 0 to 3 for eight different situations 
that most people engage in during their daily lives, 
though not necessarily every day. The scores for the 
eight questions are added together to obtain a single 
number. A number in the 0-9 range is considered to be 
normal, while a number in the 10-24 range indicates 
that expert medical advice should be sought. For 
instance, scores of 11-15 are shown to indicate the 
possibility of mild to moderate sleep apnea, where 
a score of 16 and above indicates the possibility of 
severe sleep apnea or narcolepsy[10]. 
The IRLSSG[1] evaluation is based on the assessment 
of the following five questions, with the necessary 
fulfillment of three or more: (1) An urge to move 
the legs, usually accompanied by uncomfortable and 
unpleasant sensations in the legs; (2) which begins 
or worsens during periods of rest or inactivity; (3) 
which occurs only or is worse in the evening or night 
than during the day; (4) which is partially or totally 
relieved by repeated leg movements; and (5) for 
which the occurrence of the above features is not 
solely accounted for by another medical or behavioral 
condition.
The IRLS score[11,12] consists of a set of 10 self-
administered questions, each of which is scored on a 
scale extending from 0 to 4. The scores of individual 
questions are aggregated to yield a total score ranging 
from 0 to 40. Based on the IRLS score, RLS is graded 
as mild (0-10), moderate (11-20), severe (21-30), or 
very severe (31-40). 
The drugs used to treat RLS belong to many different 
pharmacological classes, including the dopaminergic 
agents, opioids, benzodiazepines and antiepileptic drugs. 
We decided to avoid the employment of opioids and 
benzodiazepine due to the hepatic conditions. Therefore, 
the first-choice drug was pramipexole, a dopamine 
agonist[14] .
Neurological examinations and laboratory tests 
were performed at the beginning, after 2 wk, at the 
28th, 75th, 105th, 135th and 165th day, and at the final 
day of the follow-up, the 205th day. If major side 
effects induced by the neurological therapy occurred, 
such as nausea, vomiting, somnolence, hypotension or 
optical illusions, the pramipexole was stopped.
The second-choice drug was gabapentin, due to 
its beneficial properties and to the limited hepatic side 
effects[15-18]. 
Another aim of this study was to define the 
augmentation phenomenon in the liver patients. 
Table 1  Baseline general conditions of patients recruited
Characteristic Hepatic failure, n  = 211
Male/female 107/104
Age in year, mean and standard deviation 59 ± 4.7
(median range) (36-74)
BMI, kg/m2 25.43 ± 4.1
Cause of liver disease, n 211
   Previous alcohol abuse 139
   Hepatic venous outflow tract obstruction 14
   Cryptogenic 12
   Liver primary tumor 46
Child-Pugh class; number 211
   A 132
   B 54
   C 25
BMI: Body mass index.
Moretti R et al . RLS and hepatic chronic disease
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Augmentation is a characteristic phenomenon, well 
known in RLS patients, even if its mechanisms are not 
fully understood and most importantly, the possible 
inducing factors have not been identified[11,13,18]. It 
seems to be a pejorative condition of the earliest 
symptoms of RLS, or an expansion to other body 
parts, such as the trunk or upper limbs, compared 
with the initial benefits of the therapy[19]. It has been 
related to long-term duration of dopaminergic therapy, 
to higher dosage, and to the dopamine stimulation 
(up to 14.2%-73% with L-DOPA, and from 8.3 up to 
70% with dopamine agonists)[19-22]. Opioid analgesics, 
such as tramadol, methadone and oxycodone, may 
be considered for RLS treatment; although, trials 
reviewing long-term efficacy are lacking. The potential 
for abuse and adverse effects including dizziness, 
nausea and constipation limit the usefulness of these 
medications. In addition, tramadol has been rarely 
associated with RLS symptom augmentation[23]. 
As far as we know, no study has ever been conducted 
in hepatic patients to consider this phenomenon.
Titration, side effects, augmentation phenomenon 
and whichever alterations in laboratory test findings 
were checked and are reported here. 
All procedures complied with ethical standards 
for human investigations and the principles of the 
Declaration of Helsinki. All the patients gave written 
informed consent for participation at the first visit.
RESULTS
Baseline characteristics of patients are reported in 
Tables 1 and 2. A synopsis of the various test scores 
are reported in Table 3.
Patients were moderately depressed, with evident 
nocturnal sleep problems and a concomitant daily 
sleepiness. The most relevant aspect is that the 
sleep problem had been underestimated, and RLS 
syndrome had not been considered before the 
neurological visit, since 211/211 patients fulfilled the 
IRLSSG criteria for RLS. 
All the patients pointed out that their involuntary 
leg movements had not been considered previously, 
or had been interpreted as neuropathic pain and 
therefore treated with nonsteroidal antiinflammatory 
drug. Of the 211 RLS patients, 22 considered their 
symptoms as mild, according to IRSL, but 189 found 
them moderate to very severe (Table 3).
Patients were moderately depressed according 
to an objective test, such as the Hamilton scale. 
Symptoms included depressed mood, insomnia, work 
and activities production, retardation as slowness of 
thought and speech, anxiety and somatic symptoms, 
insight and diurnal variation, and not in the more 
psychiatric-related scores, such as feelings of guilt, 
suicide thoughts, agitation, genital symptoms, 
hypochondriasis, loss of weight, depersonalization 
and derealization, paranoid symptoms, obsession and 
compulsive symptoms.
A Spearman’s rank correlation analysis showed the 
following: (1) A positive correlation between IRLSSG 
fulfillment criteria and poor nocturnal sleep quality 
(PSQI: r = 0.89, P < 0.01); (2) a positive correlation 
between IRLSSG fulfillment criteria and excessive 
diurnal sleepiness (ESS: r = 0.92, P < 0.01); (3) a 
positive correlation between IRLSSG fulfillment criteria 
and Hamilton’s score (r = 0.76, P < 0.05); and, (4) 
a positive correlation between the four levels of IRSL 
and PSQI (IRSL 0-10 vs PSQI: r = 0.71, P < 0.05; 
IRSL 11-20 vs PSQI: r = 0.78, P < 0.05; IRSL 21-30 
vs PSQI: r = 0.83, P < 0.01; IRSL 31-40 vs PSQI: 
r = 0.89, P < 0.01). There was no correlation found 
between ammonium level and ESS or PSQI.
At the beginning, all patients were prescribed 
pramipexole at an average dosage of 0.18 mg, to be 
taken in the evening for the first 2 week. We then 
duplicated the dosage for 2 more weeks, up to 0.36 
mg, once a day; this dosage was maintained till the 
75th day. At the 75th day, we prescribed 0.7 mg daily, 
which was then increased to 0.88 mg daily at the 
105th day. Forty-one patients reported side effects 
at the 135th day, such as persistent nausea, optical 
illusions and visual hallucinations, and decided to stop 
the pramipexole therapy (see below). The remaining 
Table 2  Baseline metabolic parameters of 211 patients recruited
Labs parameter (normal values) Average of 211 patients (range)
Hemoglobin (14-16 g/dL)     11.1 (7.5-12.3)
Platelets counts (150-400 × 1000/µL)      97 (65-423)
Serum protein (g/dL)       7.6 (3.4-10.1)
Serum bilirubin (0.1-1.3 mg/dL)    1.7 (0.9-12)
Alanine aminotransferase (8-55 IU/L)      77 (24-452)
Aspartate aminotransferase (8-48 IU/L)      71 (34-715)
International normalized ratio (INR)     1.8 (1.0-4.9)
Serum creatinine (0.6-1.2 mg/dL)     1.0 (0.6-2.1)
Serum albumin (3.7-5.0 g/dL)     3.5 (1.5-5.1)
Ammonium (40-80 µg/dL)      97 (45-134)
Folate (3.89-26.0 ng/mL)       2.3 (1.9-12.3)
Iron free level (40-150 µg/dL) 26.5 (12-89)
Ferritine (20-200 ng/mL)      235 (126-456)
Vitamin B12 ( 205-870 pg/mL)      189 (121-245)
Vitamin D-OH25 (30-100 ng/mL)      41 (12-130)
Table 3  Synopsis of the tests at baseline
Test (range) Results
Hamilton rating scale (0-66) 18.5 ± 4.5
PSQI (0-5) 3.4 ± 0.5
ESS (0-24) 11 ± 2.1
IRLSSG Fulfillment of criteria:
211/211
IRSL (0-40) 0-10 (mild) = 22
11-20 (moderate) = 76
21-30 (severe) = 109
31-40 (very severe) = 4
ESS: Excessive diurnal sleepiness; IRLS: International RLS severity scoring 
system; IRLSSG: International Restless Legs Syndrome Study Group 
evaluation; PSQI: Depression, sleep quality assessment. 
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170 patients were prescribed 1.4 mg daily, which 
seemed quite appropriate in respect of their average 
body mass index. At the following scheduled visit, 
on the 165th d, we reported that 134 patients (65%) 
felt well with the 1.4 mg/daily dose (the maximum 
allowed dosage being 2.1 mg daily). On the contrary, 
36 patients (25%) reported the reappearance of 
unpleasant sensations in their legs and feet, with 
the urgency to rise up and move, during night and 
early morning (augmentation phenomenon). These 
patients were treated with 0.88 mg daily. At the 
205th day, 110 patients (52%) continued to feel good 
with the 1.4 mg daily dosage; on the other hand, 60 
patients (48%) reported the augmentation symptoms 
and were titrated to 0.7 mg daily (Table 4).
The 41 patients who abandoned pramipexole, after 
2 wash-out weeks, were administered gabapentin at 
100 mg daily for 10 d, then 200 mg daily for 20 d, 
and then 300 mg for 40 d. At the 105th day, 6 patients 
(14%) required 400 mg daily. At the 135th day, 11 
patients (27%) needed 500 mg gabapentin daily. At 
the 165th day, 14 patients (34%) needed gabapentin 
up to 600 mg daily, and at the 205th day, 25 patients 
(61%) needed 600 mg gabapentin (Table 5).
Considering the 170 patients who completed the 
205 d of follow-up with pramipexole, the results were 
rather satisfactory (Table 6), with an evident and 
constant amelioration of depression, of sleep quality 
and of daily sleepiness, as far as Wilcoxon signed rank 
test within-group comparison (vs baseline) showed. At 
the final visit, their subjective feeling of the intensity of 
RLS disturbances was perceived as mild to moderate 
in 155 patients and severe in 15 of them. Nobody 
declared a very severe score (Table 6).
The 41 patients who abandoned pramipexole, due 
to side effects, were treated with gabapentin (Table 5). 
According to a Wilcoxon signed rank test, there was a 
slight worsening of nocturnal sleep quality, significantly 
evident at the 205th day (Table 7) according to 
reporting of an increase in daily sleepiness. The quality 
of RLS disturbances was perceived at final visit as mild 
to moderate in 29 patients and severe in 2 of them. 
All the 41 patients who took gabapentin reported 
abdominal weight gain (5.2 ± 1.1 kg, range: 2.4-7.6) 
at the final visit.
We have determined the onset of augmentation 
symptoms in 170 patients who carried on with 
pramipexole. Logistic regression analysis to identify 
factors associated with the augmentation was 
performed with independent variables, including 
age, body mass index, IRLS alcohol abuse, iron-free 
levels, folate, vitamin B12 and D-OH25, alanine and 
Table 4  Synopsis of pramipexole titration
Patients Baseline 75th day 105th d 135th day 165th day 205th day
211 0.18 mg
211 0.7 mg
211 0.88 mg
170 1.4 mg
134 1.4 mg
36 0.88 mg
110 1.4 mg
60 0.7 mg
Table 5  Synopsis of gabapentin titration
Patients 45th day 75th day 105th day 135th day 165th day 205th day
41 100 mg
41 300 mg
35 300 mg
6 400 mg
30 300 mg
11 500 mg
27 300 mg
14 600 mg
16 300 mg
25 600 mg
Table 6  Results for pramipexole therapy during follow-up of 
170 patients 
Test (range) 135th day 165th day 205th day
Hamilton rating 
scale (0-66)
9.2 ± 0.1 8.7 ± 1.3 9.0 ± 1.1
(-9.3 ± 3.0; < 0.01) (-9.8 ± 1.7; < 0.01) (-9.5 ± 0.2; < 0.01)
PSQI (0-5) 2.2 ± 0.7 1.9 ± 0.7 2.3 ± 0.7
(-1.2 ± 0.2; < 0.05) (-1.32 ± 0.2; < 0.05) (-1.1 ± 0.2; < 0.05)
ESS (0-24) 8. 3 ± 0.7 8. 5 ± 0.4 8 .7 ± 1.1
(-7.1 ± 0.4; < 0.01) (-7.3 ± 0.7; < 0.01) (-7.7 ± 0.2; < 0.01)
IRSL (0-40) 0-10 (mild) = 51 134 110
11-20 (moderate) 
= 100
12 45
21-30 (severe) 
= 19
14 15
31-40 (very 
severe) = 0
0 0
Within-group analysis was done by comparing results at each day’s visit 
vs baseline. ESS: Excessive diurnal sleepiness; IRLS: International RLS 
severity scoring system; PSQI: Depression, sleep quality assessment. 
Table 7  Results for gabapentin therapy during follow-up of 
41 patients
Test (range) 135th day 165th day 205th day
Hamilton rating 
scalec(0-66)
9.7 ± 0.4 9.7 ± 0.5 10.0 ± 0.7
(-9.8 ± 0.2; < 0.01) (-9.8 ± 0.3; < 0.01) (-9.9 ± 1.2; < 0.01)
PSQI (0-5) 2.7 ± 0.7 2.9 ± 0.3 3.0 ± 0.5
(+ 0.7 ± 0.2; NS) (+0.5 ± 0.2; NS) (+0.6 ± 0.3; NS)
ESS (0-24) 9 9 ± 0.7 9. 5 ± 0.4 12 .7 ± 1.1
(-0.7 ± 1.0; NS) (-0.5 ± 0.1; NS) (-3.3 ± 0.1; < 0.05)
IRSL (0-40) 0-10 (mild) = 21 18 17
11-20 
(moderate) = 14
19 22
21-30 
(severe) = 6
4 2
31-40 
(very severe) = 0
0 0
Within-group analysis was done by comparing results at each day’s visit vs 
the 45th day results. ESS: Excessive diurnal sleepiness; IRLS: International 
RLS severity scoring system; NS: Nonsignificant; PSQI: Depression, sleep 
quality assessment. 
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aspartate aminotransferases, treatment duration of 
pramipexole, and daily pramipexole doses. Univariate 
and multivariate logistic regression analyses were 
performed, and the Wald test was used to assess 
the significance of each variable, as reported in Table 
8. Daily pramipexole dose, duration of treatment, 
previous alcohol abuse, iron-free levels as well as lower 
levels of B12, D-OH25 and folate were significantly 
associated with augmentation in univariate analysis 
(Table 8). On the other hand, abuse of alcohol, dose of 
pramipexole and its duration, level of vitamin B12 and 
D-OH25 and of folate, in the multivariate regression 
analysis, seemed to be significantly associated with 
augmentation (Table 8).
DISCUSSION
In this study, we found that patients with chronic liver 
disease, such as liver cirrhosis or primitive tumors, 
who were referred for sleep disorders might have RLS 
as well. The presence of RLS was not associated with 
sex, and cause or severity of the liver disease was in 
line to what has been demonstrated by Goel et al[7]. 
As previously reported[3], many causative factors can 
induce RLS in hepatic chronic disease patients, such 
as low iron levels, high ferritin levels and associated 
low folate and vitamin B12 levels. It has also been 
described that the increased prevalence of RLS in 
chronic medical conditions (such as renal failure 
and, limited to few studies, hepatic failure) might be 
related to altered electrolyte levels, such as diuretic-
induced hypokalemia, dilutional and diuretic-induced 
hyponatremia, hypocalcemia, or hypomagnesemia. 
Furthermore, it is possible that vitamin D deficiency, 
reduced physical activity, reduced muscular tone and 
increased serum levels of endotoxins and inflammatory 
cytokines (due to porta-systemic shunting resulting in 
low-grade inflammation) account for this phenomenon.
In particular, iron deficiency (present in all our 
patients) has been associated with dopamine pathology 
in RLS[24]. More specifically, it has been hypothesized 
that brain iron deficiency produces a dopaminergic 
pathology, resulting in the RLS symptoms[2]. Cerebral 
spinal fluid (CSF), autopsy and brain imaging studies 
clearly showed the expected brain iron deficiency, 
particularly affecting the dopamine-producing cells 
in the substantia nigra and their terminal fields in 
the striatum. A low content of iron in the brain is a 
well-established finding of RLS[24,25]. The dopamine 
pathology was, however, elusive and only recently has 
it been more clearly identified. 
Animal and cellular iron deficiency studies have 
shown an increased activity of tyrosine hydroxylase 
in the substantia nigra[26] and decreased D2 receptors 
in the striatum[26]. These variations were associated 
with a decreased function of the cell membrane 
dopamine transporter[28] with increased concentration 
of the extracellular dopamine, with a 4-times 
increase in the amplitude of the circadian variation 
of extracellular dopamine (night-day difference)[29]. 
These same findings have been confirmed in RLS 
patients[2]. The CSF of these patients has significantly 
more 3-O-methyldopa, that correlates with the CSF 
homovanillic acid and RLS severity, indicating that 
increased dopamine production is proportional to 
the severity of RLS symptoms[30]. Moreover, the 
CSF tetrahydrobiopterin is significantly increased in 
the morning compared to night[30], and this finding 
is consistent with the larger circadian extracellular 
dopamine pattern observed in the iron-deprived rat. 
As pointed out by Salas et al[2], RLS, unlike 
Parkinson’s disease, is a hyper-dopaminergic condition 
with an apparent postsynaptic desensitization that 
overcompensates during the circadian low point of 
dopaminergic activity in the evening and night. This 
overcompensation leads to the RLS symptoms that can 
be easily corrected by adding dopamine stimulation at 
that time. The primary finding from multiple studies 
indicates that the iron deficiency affects dopaminergic 
function, by increasing tyrosine hydroxylase, which 
then increases extracellular dopamine[2,32-34]. Our study 
confirms an effective and rapid benefit by the use of 
dopamine agonist (as well-recognized and reported in 
the literature[3,32,33]). 
On the other hand, RLS is a hyperdopaminergic 
condition, with an apparent postsynaptic desensitization 
that overcompensates during the circadian low point 
of dopaminergic activity in the evening and night. This 
overcompensation leads to the RLS symptoms that in 
turn often lead to increasing postsynaptic desensitization 
and augmentation of the RLS[2,32,34-36]. In fact, patients 
with RLS with mood and stress states may be at greater 
risk of developing compulsive behaviors while receiving 
standard dosage treatment of dopamine agonists (but 
Table 8  Analysis of factors for association with the presence 
of augmentation
Factor n Univariate Multivariate
OR (95%CI) P  value OR (95%CI) P  value
Age 170 1.07 (0.7-1.2)  0.24   1.1 (0.9-1.3)  0.20
BMI 170   1.3 (0.9-1.5)  0.45   1.6 (1.0-1.9)  0.40
IRLS 170   1.5 (1.1-2.2)  0.36   1.7 (1.2-2.2)  0.57
Alcohol abuse 139   2.3 (0.9-4.1) < 0.001 3.75 (2.7-6.2) < 0.001
Daily 
pramipexole
170   3.6 (2.1-6.8) < 0.001     7.2 (4.1-15.2) < 0.001
Treatment 
duration, 
> 75 d/< 75 d
170   2.3 (1.3-4.2)    0.036     6.6 (3.1-11.2)  0.01
ALT 170   1.3 (0.9-1.6)  0.21   3.1 (1.7-3.9)  0.54
AST 170   1.6 (0.8-1.7)  0.50   2.7 (0.7-4.2)  0.76
Iron-free level 170   2.9 (0.9-4.1)  0.01   5.05 (1.1-12.2)  0.06
Vit. B12 170 4.25 (1.3-9.7)  0.01   6.9 (4.7-7.6)  0.01
Folate 170     4.1 (3.1-13.6)  0.01   5.7 (4.2-8.2)  0.01
Vit. D-OH25 170     4.8 (3.4-12.9)  0.01 5.67 (2.4-8.9)  0.01
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; BMI: 
Body mass index; CI: Confidence interval; IRLS: International restless leg 
syndrome severity; OR: Odds ratio; Vit.: Vitamin.
Moretti R et al . RLS and hepatic chronic disease
385 March 27, 2018|Volume 10|Issue 3|WJH|www.wjgnet.com
also of other drugs, such as tramadol[22]). 
It appears evident that RLS remains a still 
confounding, not immediately recognized condition 
requiring rapid diagnosis and treatment. Augmentation 
seems rather precocious in our patients (135th day) 
and more frequent (35%) than previously described 
by Ferini-Strambi (8.3%)[20] and by Takahashi et al[22] 
(9.1%). The dosage of dopamine agonists found to be 
associated with augmentation in this study appears 
in range with the literature[14,19-22]. Previous intake of 
alcohol and lower levels of vitamins have been related 
to the phenomenon in our study.
RLS is a major cause of insomnia, and the structure 
of sleep of sufferers may be severely impaired. Sleep 
disruption has, in consequence, a great impact on 
health and daytime functioning of RLS patients. Despite 
the fact that RLS is a very common disorder, it is 
frequently undiagnosed in primary care, and therefore 
inadequate therapy may be prescribed. 
Additional neurophysiologic studies and more 
extended clinical trials are strenuously needed to explain 
some crucial pathologic mechanisms of the syndrome, 
in order to better employ common therapeutic agents 
and to find novel ones. 
ARTICLE HIGHLIGHTS
Research background
Restless legs syndrome (RLS) remains a clinical diagnosis based on confirming 
the four essential diagnostic features of RLS, including: (1) An urge to move 
the legs, usually but not always accompanied by or felt to be caused by 
uncomfortable and unpleasant sensations in the legs; (2) the urge to move, 
as any accompanying unpleasant sensation begins or worsens during periods 
of rest or inactivity, such as lying down or sitting; (3) the urge to move, as any 
accompanying unpleasant sensation is partially or totally relieved by movement, 
such as walking or stretching; and (4) the urge to move, as any accompanying 
unpleasant sensation during rest or inactivity only occurs or is worse in the 
evening or night compared to during the day. Chronic medical situations (dialysis, 
end-stage renal disease and rheumatologic disorders) have a higher prevalence 
of RLS.
Research motivation
An increased prevalence of RLS has been described in patients with liver cirrhosis 
in the United States and Japan. Very recently, RLS has been described in India in 
a series of chronic hepatic failure patients. Data in hepatic patients are limited.
Research objectives 
According to neurological exams, the diagnosis of RLS was suggested by the 
Johns Hopkins questionnaire and verified by fulfillment of the diagnostic criteria 
by Allen. Iron-free level, ferritin, folate and vitamin B12 and vitamin D-OH25 
were measured in all patients. Drugs used to treat RLS belong to many 
different pharmacological classes, such as the dopaminergic agents, opioids, 
benzodiazepines and antiepileptic drugs. We decided to avoid the employment 
of opioids and benzodiazepine due to the hepatic conditions. Therefore, the 
first-choice drug was pramipexole, a dopamine agonist. The second-choice 
drug was gabapentin, due to its beneficial properties and to the limited hepatic 
side effects. Neurological examinations and laboratory tests were performed at 
the beginning, after 2 wk, at the 28th, 75th, 105th, 135th and 165th day, and at the 
final day of the follow-up, the 205th day. Another aim of this study was to define 
the augmentation phenomenon in the liver patients. 
Research methods
The study included 267 adult patients with chronic liver disease, referred to 
our Neurological Unit by the Liver Unit of the University of Trieste, for three 
complaints, including sleep disturbances, painful leg sensation, and daily 
sleepiness not correlated to hepatic encephalopathy. Patients with chronic liver 
disease included primary liver tumor and liver cirrhosis cases. We excluded 13 
patients with chronic and persistent significant alcohol intake, 25 patients with 
recent worsening of clinical condition, and 12 patients with hepatitis C virus 
infection. All the other 211 patients were followed up by a neurologist for at 
least 24 mo. At baseline, patients were tested with the Hamilton rating scale for 
depression, sleep quality assessment (PSQI), Epworth sleepiness scale (ESS), 
International Restless Legs Syndrome Study Group (IRLSSG) evaluation, and 
international RLS severity (IRLS) scoring system. Alterations in titration, side 
effects, augmentation phenomenon and laboratory test findings were checked 
and reported. The first-choice drug was pramipexole, a dopamine agonist. 
If major side effects induced by the neurological therapy occurred, such as 
nausea, vomiting, somnolence, hypotension or optical illusions, the pramipexole 
was stopped. The second-choice drug was gabapentin, due to its beneficial 
properties and to the limited hepatic side effects. Another aim of this study was 
to define the augmentation phenomenon in the liver patients. 
Research results
Patients included in the study fulfilled the IRLSSG criteria for RLS; they 
were moderately depressed, with evident nocturnal sleep problems and a 
concomitant daily sleepiness. Of the 211 RLS patients, 22 considered their 
symptoms as mild, according to IRSL, but 189 found them moderate to very 
severe. A Spearman’s rank correlation analysis showed the following: (1) a 
positive correlation between IRLSSG fulfillment criteria and poor nocturnal sleep 
quality (PSQI); (2) a positive correlation between IRLSSG fulfillment criteria and 
excessive diurnal sleepiness (ESS); (3) a positive correlation between IRLSSG 
fulfillment criteria and Hamilton’s score; (4) a positive correlation between the 
four levels of IRSL and PSQI; and (5) no correlation between ammonium level 
and ESS or PSQI. At the beginning, all patients were prescribed pramipexole at 
an average dosage of 0.18 mg, to be taken in the evening for the first 2 week. 
Titration was standard; we duplicated the dosage for 2 more weeks, up to 0.36 
mg, till the 75th day. At the 75th day, we prescribed 0.7 mg daily, which was then 
increased to 0.88 mg daily at the 105th day. Forty-one patients reported heavy 
side effects at the 135th day and decided to stop the pramipexole therapy. The 
remaining 170 patients were prescribed 1.4 mg daily, which seemed quite 
appropriate in respect of their average body mass index. At the 205th day, 110 
patients (52%) continued to feel good with the 1.4 mg daily dosage; on the other 
hand, 60 patients (48%) reported the augmentation symptoms and were titrated 
at 0.7 mg daily. The 41 patients who abandoned pramipexole, after 2 wash-
out weeks, were administered gabapentin, at increasing dosages. Considering 
the 170 patients who completed the 205 d of follow-up with pramipexole, the 
results were rather satisfactory, with an evident and constant amelioration of 
depression, of sleep quality and of daily sleepiness, as far as Wilcoxon signed 
rank test within-group comparison (vs baseline) showed. At the final visit, 
their subjective feeling of the intensity of RLS disturbances was perceived as 
mild to moderate in 155 patients and severe in 15 of them. Nobody declared 
a very severe score. The 41 patients who abandoned pramipexole, due to 
side effects, were treated with gabapentin, reporting a slight worsening of 
nocturnal sleep quality and an increase of daily sleepiness. All the 41 patients 
who took gabapentin reported abdominal weight gain at the final visit. As far as 
the augmentation phenomenon was concerned, a logistic regression analysis 
to identify factors associated with the augmentation were performed with 
independent variables, including age, body mass index, IRLS alcohol abuse, 
iron-free levels, folate, vitamin B12 and D-OH25 levels, alanine and aspartate 
aminotransferase, treatment duration of pramipexole, and daily pramipexole 
doses. Univariate and multivariate logistic regression analyses were performed 
and the Wald test was used to assess the significance of each variable. Daily 
pramipexole dose, the duration of the treatment, previous alcohol abuse, iron-
free levels as well as lower levels of B12, D-OH25 and folate were significantly 
associated with augmentation in univariate analysis. On the other hand, abuse 
of alcohol, dose of pramipexole and its duration, level of vitamin B12 and 
D-OH25 and of folate, in the multivariate regression analysis, seemed to be 
significantly associated with augmentation.
Research conclusions
In this study, we found that patients with chronic liver disease, such as liver 
cirrhosis or primitive tumors, who were referred for sleep disorders might have 
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RLS as well. The presence of RLS was not associated with sex, and cause 
or severity of the liver disease was in line with what has been demonstrated 
by the few other studies. As previously reported, in our study, many causative 
factors induce RLS in hepatic chronic disease patients, such as low iron levels, 
high ferritin levels, and associated low folate and vitamin B12 levels. Our study 
confirms an effective and rapid benefit for the use of dopamine agonist (as is 
well-recognized and reported in the literature). On the other hand, RLS is a 
hyperdopaminergic condition with an apparent postsynaptic desensitization that 
overcompensates during the circadian low point of dopaminergic activity in the 
evening and night. This overcompensation leads to the RLS symptoms that in 
turn often lead to increasing postsynaptic desensitization and augmentation 
of the RLS. In fact, patients with RLS with mood and stress states may be 
at greater risk of developing compulsive behaviors while receiving standard 
dosage treatment of dopamine agonists (but also of other drugs, such as 
tramadol). Augmentation seems rather precocious in our patients (135th day), 
and more frequent (35%) than previously described by the most important 
study on the topic (8.3%-9.1%). The dosage of dopamine agonists reported in 
our study to be associated with augmentation appears to be in range with the 
literature. Previous intake of alcohol and lower levels of vitamins were related to 
the phenomenon in our study.
Research perspectives
It appears evident that RLS remains a still confounding, not immediately 
recognized condition requiring rapid diagnosis and treatment. Despite the 
fact that RLS is a very common disorder, it is frequently undiagnosed in 
primary care, and therefore inadequate therapy may be prescribed. Additional 
neurophysiologic studies and more extended clinical trials are strenuously 
needed to explain some crucial pathologic mechanisms of the syndrome, in 
order to better employ common therapeutic agents and to find novel ones. 
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